The FDA has granted Fast Track designation to Elisigen's gene therapy candidate 'NG101' for the treatment of wet AMD. This designation recognizes the therapeutic potential of NG101 and will facilitate expedited development and review processes through close collaboration with the FDA.
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.